Capital World Investors
BHVN

Capital World Investors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Capital World Investors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-841,900
Closed -$127M – 573
2022
Q3 		$127M Sell
841,900
-1,800,734
-68% -$267M 0.03% 312
2022
Q2 		$385M Sell
2,642,634
-3,999,905
-60% -$511M 0.08% 211
2022
Q1 		$788M Buy
6,642,539
+464,530
+8% +$57.9M 0.14% 167
2021
Q4 		$851M Buy
6,178,009
+115,628
+2% +$14.7M 0.13% 160
2021
Q3 		$842M Buy
6,062,381
+754
+0% +$94.1K 0.14% 159
2021
Q2 		$588M Buy
6,061,627
+1,321,691
+28% +$107M 0.1% 197
2021
Q1 		$324M Buy
4,739,936
+90,488
+2% +$7.32M 0.06% 242
2020
Q4 		$399M Buy
4,649,448
+1,340,473
+41% +$114M 0.08% 222
2020
Q3 		$215M Buy
3,308,975
+1,110,384
+51% +$72.8M 0.05% 259
2020
Q2 		$161M Buy
2,198,591
+737
+0% +$39.2K 0.04% 268
2020
Q1 		$74.8M Buy
2,197,854
+551,428
+33% +$25.2M 0.02% 296
2019
Q4 		$89.6M Buy
1,646,426
+1,176,426
+250% +$58.3M 0.02% 315
2019
Q3 		$19.6M Hold
470,000
– – ﹤0.01% 410
2019
Q2 		$20.6M Buy
+470,000
New +$26.5M ﹤0.01% 437

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Capital World Investors's BHVN Position: Q4 2022 in Review

Capital World Investors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 841,900 shares — an estimated $127M sold.

Capital World Investors first reported a position in BHVN in Q2 2019 and held it in 14 quarters. The position peaked at $851M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Capital World Investors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Capital World Investors sold 841,900 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $127M.
  • Capital World Investors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 14 quarters.
  • Capital World Investors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $851M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Capital World Investors's 13F filing for Q4 2022, filed 14 Feb 2023.